Oncology & Cancer

Tarloxotinib promising against NRG1-fusion cancers

A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active ...